Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

The main market opportunities for PD-L1 x 4-1BB bispecific antibodies lie in their ability to enhance antitumor responses while minimizing liver toxicity by focusing activation within the tumor ...

SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading ...

The EMA has started a review of a regimen based on Pfizer and Astellas' Padcev and MSD's Keytruda that has been described as ...

The following highlights showcase key research presented at the European Society for Medical Oncology (ESMO) 2025 Congress.

The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...

Tumor treating fields are emerging as a promising option for treating a range of cancer types. Here’s a look at the evidence ...

The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as neoadjuvant and ...

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an announcement. Shanghai Henlius Biotech, Inc. announced that its ...

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ETOCALA, ...